New options for the anemia of chronic kidney disease

Anemia is a common complication of chronic kidney disease. Use of erythropoiesis-stimulating agents (ESA) has been a mainstay of treatment since 1990. A series of large trials demonstrated that ESAs have serious safety problems, including increasing cardiovascular and thrombotic events, and death. A...

Descripción completa

Detalles Bibliográficos
Autores principales: Coyne, Daniel W., Goldsmith, David, Macdougall, Iain C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341017/
https://www.ncbi.nlm.nih.gov/pubmed/30675430
http://dx.doi.org/10.1016/j.kisu.2017.09.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341017/
https://www.ncbi.nlm.nih.gov/pubmed/30675430
http://dx.doi.org/10.1016/j.kisu.2017.09.002

Ejemplares similares